| Purpose | Patients | Evaluations | Perceived Effectiveness |
|---|---|---|---|
| Systemic lupus erythematosus | 22,740 | 788 | |
| Rheumatoid arthritis | 3,657 | 397 | |
| Mixed connective tissue disease | 642 | 85 | |
| Undifferentiated connective tissue disease | 448 | 59 | |
| Subacute cutaneous lupus erythematosus | 180 | 15 |
Common side effects
| Side effect | Patients | Percentage |
|---|---|---|
| Nausea | 116 | |
| Diarrhea | 59 | |
| Blurry vision | 45 | |
| Headaches | 34 | |
| Stomach pain | 29 | |
| Dizziness | 21 |
Side effect severity
| Severity | Evaluations | Percentage |
|---|---|---|
| Severe | 173 | |
| Moderate | 218 | |
| Mild | 301 | |
| None | 719 |
Member evaluations
psyclops
evaluated on Oct 01, 2021
- Perceived effectiveness for systemic lupus erythematosus: Major
- Side effects: None
origin
evaluated on Jan 09, 2019
- Perceived effectiveness for Sjogren's syndrome: Can't tell
- Side effects: Mild
alf53
evaluated on Jun 29, 2001
- Perceived effectiveness for mixed connective tissue disease: Slight
- Side effects: None